Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
By H. Nair, D. Nokes, B. Gessner, M. Dherani, S. Madhi, R. Singleton, Katherine L. O’Brien, Anna Roca, Peter F. Wright, Nigel G Bruce and 11 more. The Lancet, 2010
2,581 citations recorded by the source corpus.
Summary Background The global burden of disease attributable to respiratory syncytial virus (RSV) remains unknown. We aimed to estimate the global incidence of and mortality from episodes of acute lower respiratory infection (ALRI) due to RSV in children younger than 5 years in 2005. Methods We estimated the incidence of RSV-associated ALRI in children younger than 5 years, stratified by age, using data from a systematic review of studies published between January, 1995, and June, 2009, and ten unpublished population-based studies. We estimated possible boundaries for RSV-associated ALRI mortality by combining case fatality ratios with incidence estimates from hospital-based reports from published and unpublished studies and identifying studies with population-based data for RSV seasonality and monthly ALRI mortality. Findings In 2005, an estimated 33·8 (95% CI 19·3–46·2) million new episodes of RSV-associated ALRI occurred worldwide in children younger than 5 years (22% of ALRI episodes), with at least 3·4 (2·8–4·3) million episodes representing severe RSV-associated ALRI necessitating hospital admission. We estimated that 66 000–199 000 children younger than 5 years died from RSV-associated ALRI in 2005, with 99% of these deaths occurring in developing countries. Incidence and mortality can vary substantially from year to year in any one setting. Interpretation Globally, RSV is the most common cause of childhood ALRI and a major cause of admission to hospital as a result of severe ALRI. Mortality data suggest that RSV is an important cause of death in childhood from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b. The development of novel prevention and treatment strategies should be accelerated as a priority. Funding WHO; Bill & Melinda Gates Foundation.
Subfields: Animal Science and Zoology, Epidemiology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/a50758fd20e3740b75a3785139b37811d77d3460
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention (2012, neutral): “H respiratory syncytial virus (hRSV) is the most important viral cause of severe respiratory tract disease in the pediatric population worldwide (1) and is also of considerable importance in the elderly and immunocompromised adults (2).”
- Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes (2011, positive): “RSV is a leading cause of pneumonia and bronchiolitis in infants and the elderly and is estimated to cause 30 million lower respiratory tract infections and more than 60,000 deaths worldwide each year (32).”
- Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers (2011, positive): “R syncytial virus (RSV) is the most common cause of acute lower respiratory infection among children worldwide and the leading cause of infant hospitalization for respiratory disease in developed countries (1, 2).”
- The Airway Epithelium: Soldier in the Fight against Respiratory Viruses (2011, neutral): “They lead to more than 400,000 hospitalizations per year among children in the United States and are therefore a major burden on the health care system (105, 180, 194).”
- Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses (2016, neutral): “66,000 to 199,000 deaths, mainly in developing countries (1).”
- Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? (2019, positive): “Respiratory syncytial virus (RSV), a member of the Orthopneumovirus genus [112] , infects approximately 70% of infants before the age of 1 and almost 100% by the age of 2 years old [113] , making it the most common pathogen to cause lower respiratory tract infection such as bronchiolitis and pneumon”
- Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine (2016, neutral): “Human respiratory syncytial virus (RSV) infects virtually all children by two years of age and accounts for ~50% of hospitalizations due to respiratory infections in this age group 1-4 .”